Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$GOSS

DatePrice TargetRatingAnalyst
6/25/2024$9.00Outperform
Oppenheimer
4/5/2024$4.00Outperform
Wedbush
7/27/2023$8.00 → $1.25Buy → Neutral
UBS
3/7/2023Outperform → Mkt Perform
Raymond James
3/1/2023Neutral
Guggenheim
12/7/2022Neutral → Underweight
JP Morgan
12/7/2022$3.00Outperform → Neutral
SMBC Nikko
12/7/2022$18.00 → $2.00Overweight → Equal Weight
Barclays
More analyst ratings

$GOSS
Press Releases

Fastest customizable press release news feed in the world

See more
  • Gossamer Bio Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

    - PROSERA Phase 3 in PAH on Track for Topline Data Readout in Fourth Quarter of 2025 - - Registrational Phase 3 in PH-ILD Expected to Commence in Second Half of 2025 - - Seralutinib Receives Orphan Drug Designation for PAH in Japan - - Cash, cash equivalents and marketable securities totaled $295 million at year-end 2024 - Gossamer Bio, Inc. (NASDAQ:GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the fourth quarter and year ended December

    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    Gossamer Bio, Inc. (NASDAQ:GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer's Board of Directors approved the grant, effective March 5, 2025, to five non-executive employees of non-qualified stock option awards to purchase up to an aggregate of 342,250 shares of the Company's common stock under the Gossamer Bio, Inc. 2023 Employment Inducement Incentive Award Plan ("2023 Inducement Plan"). The awards were granted as an inducem

    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now

    MIAMI, Feb. 19, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 79th Emerging Growth Conference on February 18 & 19, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter Day 2 - TodayFebruary 19, 2025 Replay Day 1 here:https://emerginggrowt

    $AEMD
    $ASPI
    $BDRX
    $BENF
    Medical/Dental Instruments
    Health Care
    Major Chemicals
    Industrials

$GOSS
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$GOSS
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$GOSS
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$GOSS
SEC Filings

See more

$GOSS
Leadership Updates

Live Leadership Updates

See more
  • Gossamer Bio Appoints Bob Smith as Chief Commercial Officer

    - Mr. Smith is a recognized leader in the commercialization of PAH products, most recently leading sotatercept US pre-launch activities at Merck - - Previously, Mr. Smith led US sales operations for Actelion - Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced the appointment of Bob Smith as its Chief Commercial Officer. "We are proud to welcome Bob Smith to the Gossamer team and his 30 years of expertise at this critical time in our company's history," said Faheem Hasnain, Chairman, Co-Founder and CEO of Gossamer Bio.

    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Gossamer Bio Announces Appointment of John Quisel, J.D., Ph.D., to its Board of Directors

    Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced the appointment of John Quisel, J.D., Ph.D., President and CEO of Disc Medicine, to its Board of Directors. "Today, we are thrilled to announce that Dr. John Quisel has joined the Gossamer team," said Faheem Hasnain, Chairman, Co-Founder and CEO of Gossamer Bio. "Not only is Dr. Quisel a recognized industry leader with a proven track record of success, but he also brings unique strategic insights and experience in PAH, which will be invaluable. We are confident that Dr. Quise

    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Gossamer Bio Announces Addition of Rainer Zimmermann, MD, as VP of Medical Affairs

    Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced that Rainer Zimmermann, MD, has joined the Company as Vice President of Medical Affairs. Dr. Zimmermann brings more than 23 years of experience within the PAH/PH space, most recently having served as the Global Medical Lead, Medical Affairs, Pulmonary Hypertension, at Johnson & Johnson Innovative Medicine. In this role, he partnered with the development and commercial teams to lead pre-launch and launch activities of several approved PAH products, including Uptravi® (selixpag),

    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

$GOSS
Financials

Live finance-specific insights

See more
  • Gossamer Bio Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

    - PROSERA Phase 3 in PAH on Track for Topline Data Readout in Fourth Quarter of 2025 - - Registrational Phase 3 in PH-ILD Expected to Commence in Second Half of 2025 - - Seralutinib Receives Orphan Drug Designation for PAH in Japan - - Cash, cash equivalents and marketable securities totaled $295 million at year-end 2024 - Gossamer Bio, Inc. (NASDAQ:GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the fourth quarter and year ended December

    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Gossamer Bio Announces Third Quarter 2024 Financial Results and Provides Business Update

    - $327 Million in Cash, Cash Equivalents & Marketable Securities, as of September 30, 2024 - Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the third quarter ended September 30, 2024 and provided a business update. "Looking forward, we expect 2025 to be an exceptionally important year for Gossamer, as we both anticipate Phase 3 PROSERA Study results in PAH and commence our PH-ILD Phase 3 study," said Faheem Hasnain, Co-

    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Gossamer Bio Announces Second Quarter 2024 Financial Results and Provides Business Update

    - $354 Million in Cash, Cash Equivalents & Marketable Securities, as of June 30, 2024 - Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the second quarter ended June 30, 2024 and provided a business update. "Between the continued progress made in the enrollment of the Phase 3 PROSERA Study and the transformational collaboration agreement with the Chiesi Group, Gossamer has made great strides in the second quarter to ad

    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

$GOSS
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more

$GOSS
Insider purchases explained

Analytical look into recent insider purchases

See more
  • Insider Analysis: Purchase at Gossamer Bio Inc. on Jun 21

    Gossamer Bio Inc. recently witnessed an insider purchase by COO/CFO Bryan Giraudo, who acquired $59,110 worth of shares consisting of 100,000 units at $0.59 per share. Insider purchases like this can provide valuable insights for investors, indicating confidence from individuals within the company about its future prospects. Examining previous insider transactions, on 2024-03-19, insiders Peterson Caryn and Aranda Richard each sold $5,343 worth of shares at $1.33, leading to a decrease in their direct ownership percentages. Similarly, on 2024-03-28, Hasnain Faheem, Giraudo Bryan, and Christian Waage sold shares worth $26,773, $7,431, and $7,430, respectively, impacting their direct ownershi

    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care